» Articles » PMID: 29692884

Use of Amniotic Membrane in the Treatment of Patients with BRONJ: Two Case Reports

Overview
Journal J Surg Case Rep
Specialty General Surgery
Date 2018 Apr 26
PMID 29692884
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The use of bisphosphonates has led to a new disease, bisphosphonate-related osteonecrosis of the jaw (BRONJ). There is currently no effective treatment for this disease; the surgical approach is controversial. The widespread use of human amniotic membrane (HAM) in surgery and the results obtained have highlighted its many potential properties, including antimicrobial, anti-inflammatory, antifibrotic and antiapoptotic, as well as its capacity for encouraging epithelialisation and cell differentiation. These properties are believed to encourage the recovery of patients with BRONJ, facilitating the wound healing process after surgical debridement of the bone. We report our experience with the use of HAM: two patients treated with patches of HAM. The follow-up to date, which includes x-rays and clinical assessments, demonstrates good levels of epithelialisation and absence of infections and pain. To conclude, the use of HAM in patients with BRONJ seems to be a promising therapeutic alternative to current conventional treatments.

Citing Articles

Preparation of human amniotic membrane for transplantation in different application areas.

Hofmann N, Rennekampff H, Salz A, Borgel M Front Transplant. 2024; 2:1152068.

PMID: 38993896 PMC: 11235369. DOI: 10.3389/frtra.2023.1152068.


Introduction to Amniotic Membranes in Maxillofacial Surgery-A Scoping Review.

Dawiec G, Niemczyk W, Wiench R, Niemczyk S, Skaba D Medicina (Kaunas). 2024; 60(4).

PMID: 38674309 PMC: 11051762. DOI: 10.3390/medicina60040663.


The Use of Human Amniotic Membrane (hAM) as a Treatment Strategy of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis of the Literature.

Sacco R, Akintola O, Sacco N, Acocella A, Calasans-Maia M, Maranzano M Medicina (Kaunas). 2023; 59(5).

PMID: 37241200 PMC: 10223182. DOI: 10.3390/medicina59050968.


Human amniotic membrane application in oral surgery-An pilot study.

Odet S, Solecki L, Meyer C, Weber E, Chatelain B, Euvrard E Front Bioeng Biotechnol. 2022; 10:968346.

PMID: 36353738 PMC: 9638044. DOI: 10.3389/fbioe.2022.968346.


Questions about Residual Cell Viability in Cryopreserved Human Amniotic Membrane and Its Impact on Clinical Applications.

Gaudet C, Solecki L, Matheaud B, Odet S, Meyer C, Louvrier A Biomedicines. 2022; 10(10).

PMID: 36289719 PMC: 9598775. DOI: 10.3390/biomedicines10102456.


References
1.
Aapro M, Abrahamsson P, Body J, Coleman R, Colomer R, Costa L . Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2007; 19(3):420-32. DOI: 10.1093/annonc/mdm442. View

2.
Talmi Y, Sigler L, Inge E, Finkelstein Y, Zohar Y . Antibacterial properties of human amniotic membranes. Placenta. 1991; 12(3):285-8. DOI: 10.1016/0143-4004(91)90010-d. View

3.
Aapro M, Silvio Monfardini , Jirillo A, Basso U . Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat Rev. 2009; 35(6):503-8. DOI: 10.1016/j.ctrv.2009.04.002. View

4.
van de Glind E, Willems H, Eslami S, Abu-Hanna A, Lems W, Hooft L . Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate. Drugs Aging. 2016; 33(5):347-53. PMC: 4837200. DOI: 10.1007/s40266-016-0344-7. View

5.
Terpos E, Sezer O, Croucher P, Garcia-Sanz R, Boccadoro M, San Miguel J . The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009; 20(8):1303-17. DOI: 10.1093/annonc/mdn796. View